The challenge of screening for early gastric cancer in China

Zong, Liang; Abe, Masanobu; Seto, Yasuyuki; Ji, Jiafu

doi:10.1016/s0140-6736(16)32226-7

Cited by 279 publications

(251 citation statements)

References 6 publications

Supporting

Mentioning

248

Contrasting

Order By: Relevance

“…115,116 Although surgery and chemotherapy for GC have made great progress, GC patients at an advanced stage remain a poor prognosis, having an extremely low 5-year survival rate. 117,118 Thus, it is urgent to find a new biomarkers for diagnosis and prognosis of GC.…”

Section: Gastric Cancermentioning

confidence: 99%

AFAP1‐AS1: A novel oncogenic long non‐coding RNA in human cancers

Zhang

Xiao

et al. 2017

Cell Proliferation

View full text Add to dashboard Cite

show abstract

Section: Gastric Cancermentioning

confidence: 99%

AFAP1‐AS1: A novel oncogenic long non‐coding RNA in human cancers

Zhang

Xiao

et al. 2017

Cell Proliferation

View full text Add to dashboard Cite

show abstract

“…As FMUUH is a tertiary cancer treatment center, patients treated there are socioeconomically and geographically diverse, so many patients have limited access to primary care. Cultural reluctance to seek treatment of cancer may also contribute . This hesitance is understandable in light of the historically low survival rate for GC; even in 2005, only 27% of patients with GC in China survived 5 years …”

Section: Discussionmentioning

confidence: 99%

Comparison of gastric cancer survival after R0 resection in the US and China

Huang

Zheng

et al. 2018

Journal of Surgical Oncology

View full text Add to dashboard Cite

Background and Objectives: Gastric cancer outcomes differ between Asian and Western countries, even when controlling for contributing factors, but whether this difference holds true for China remains inadequately studied. We sought to compare the presentation, treatment, and outcomes of patients with gastric cancer (GC) undergoing curative intent (R0) resection between the U.S. and China, and to ascertain whether geography/ institution is an independent predictor of DSS. Methods: Data were analyzed from patients with GC undergoing R0 resection at high-volume cancer centers in the U.S. (Memorial Sloan Kettering Cancer Center [MSKCC], n=1,378) and China (Fujian Medical University Union Hospital [FMUUH], n=4,262) between 2000 and 2014. Factors associated with disease-specific survival (DSS) were examined by multivariate analysis. Results: The 5-year DSS (p < 0.001) for all patients was better at MSKCC than at FMUUH, even among patients not receiving preoperative chemotherapy (p < 0.001), but stratification by sub-stage eliminated this difference (p > 0.05). Factors independently associated with DSS included age, histology, tumor size, T category, N category, gastrectomy type, and preoperative chemotherapy, but not institution. Conclusions: Although the presentation of GC patients between MSKCC and FMUUH differs, survival of patients with curatively resected GC, when matched for clinical stage, is comparable.

show abstract

“…These are feasible because at moment, high-definition and high-magnification endoscopy is widely available in urban and rural areas in China. [4] …”

Section: Discussionmentioning

confidence: 99%

“…[2,3] In a previous study, the rate of detection of EGC was about 10% to 20% in China, apparently much lower compared with 50% to 70%, or even more in Japan or Korea. [4] Therefore, it is important that we improve the EGC detection rate, and the appropriate treatment plan for EGC patients.…”

Section: Introductionmentioning

confidence: 99%

Concomitant stromal tumor and early cancer of the stomach

Xu¹,

Liang-fang²,

Lu³

et al. 2017

Medicine

View full text Add to dashboard Cite

Concomitant gastric stromal tumor (GST) and gastric cancer (GC) is uncommon; even more uncommon is a concomitant GST and early stage GC (EGC). Tumor resection by endoscopic submucosal dissection (ESD) for concomitant GST and EGC has not been reported. We sought to define the clinical importance of detection of concomitant GST and EGC during the first esophagogastroduodenoscopy (EGD), and compare the clinical outcomes of ESD versus radical surgery for the treatment of concomitant GST and EGC. Our investigation was a retrospective cohort study. Patients with concomitant GST and EGC who underwent ESD or radical surgery were enrolled at the university-affiliated hospital from January 2005 to January 2015. The detection rate of concomitant GST and EGC during the first EGD was 3/25 (12%). Among 25 patients, 14 underwent ESD and 11 underwent surgery. Mean operation time and hospital stay were significantly shorter in the ESD group than the surgery group. There were no significant differences in terms of rates of en bloc resection, complete resection, and early complications. Late complications were more common in the surgery group than in the ESD group. The median follow-up duration was 58.9 months. Three- or 5-year overall survival rates were 100% for both groups and no patient died of EGC and GST. There was no local recurrence in the 2 groups; however, 3 metachronous EGC lesions were found during the follow-up period in the ESD group as follows: the simultaneous occurrence of GST and EGC was uncommon; the detection rate of concomitant GST and EGC was very low at the first EGD; and ESD appeared to be a safe, efficient, and popular treatment option for concomitant GST and EGC, that met the ESD absolute indication, and the outcomes were comparable to those achieved with surgery.

show abstract

The challenge of screening for early gastric cancer in China

Cited by 279 publications

References 6 publications

AFAP1‐AS1: A novel oncogenic long non‐coding RNA in human cancers

AFAP1‐AS1: A novel oncogenic long non‐coding RNA in human cancers

Comparison of gastric cancer survival after R0 resection in the US and China

Concomitant stromal tumor and early cancer of the stomach

Contact Info

Product

Resources

About